Recommended administered Gamuneks® C initially at a rate of 0.01 ml / kg / min (1 mg / kg / min) during the first 30 min. With good tolerability, the rate can be gradually increased to a maximum of 0.08 ml / kg / min (8 mg / kg / min). If side effects are observed, the rate may be reduced or the infusion is interrupted until the symptoms disappear. Infusions can then be resumed at a rate optimal for the patient.
Patients with increased risk for renal dysfunction may be advised to decrease the amount of administered drug in unit time is less than 8 mg / kg / min (0.08 ml / kg / min). Data on the maximum safe dose, concentration and rate of administration for patients at risk of developing renal dysfunction are absent. In these conditions, all parameters should be at the lowest level of the practiced indicators.
Before administration, the drug should be visually inspected for absence of foreign particles, turbidity and discoloration.
To puncture the plug when taking the drug from a vial containing 10 ml of the drug, only size 18 needles should be used. Needles of size 16 or distributing piercers should be used only for vials containing 25 ml or more of the preparation. The needle should pierce the plug perpendicular to the plane only within the designated circle.
The contents of the vials can be connected under aseptic conditions to sterile packets and used within 8 hours after combining.
Primary humoral immunodeficiency (PGI)
A single dose of Gamunex® C is 300 to 600 mg / kg (3 and 6 ml / kg). Doses should be individualized taking into account the intervals between infusions (3 or 4 weeks).
Idiopathic thrombocytopenic purpura (ITP)
The gamunex® C can be used in a total dose of 2 g / kg divided into two doses of 1 g / kg (10 ml / kg) administered two consecutive days or 5 doses of 0.4 g / kg (4 ml / kg) administered for 5 consecutive days. If after introduction of one of two doses of 1 g / kg (10 ml / kg) there is an adequate increase in platelets by 24 h, the second dose can not be administered.The dose of 1 g / kg (10.0 ml / kg) is not recommended for dehydrated patients.
Chronic inflammatory demyelinating polyneuropathy (CVD)
The initial total dose of Gamunex® C is 2 g / kg (20 ml / kg) and is administered in 2 or 4 consecutive daily doses. The maintenance total dose of the drug is 1 g / kg (10 ml / kg), which is administered simultaneously or for 2 consecutive days at 0.5 g / kg (5 ml / kg). The interval between doses is 3 weeks. The duration of treatment is determined by positive manifestations during the course of the disease.
Bone marrow transplantation
Although no clinical trials of Gamunex® C have been performed in this category of patients, the data obtained with the analogue of this drug Gamimun indicate the advisability of using Hamunex in adult patients in bone marrow transplantation.
The recommended dose of Gamunex® C in individuals over the age of 20 is 500 mg / kg (5 ml / kg). The drug is administered 7 and 2 days before transplantation and then weekly for 3 months.
HIV infection in children
There were no clinical trials of Gamunex® C in HIV-infected children. However, the analogue of Gamunex® C, an intravenous human immunoglobulin Gamimun, is recommended at a dose of 400 mg / kg (4 ml / kg). The drug is administered at intervals of 28 days.